On Mar. 26, 2020, iBio announced that immunization studies for its SARS-CoV-2 Virus-Like Particle program (‘IBIO-200’) were proceeding at Texas A&M University System laboratories. The work was being performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016.